Mutational Resistance Expected with Mass Indiscriminate Nirsevimab Injection of Infants

Written by Peter A. McCullough, MD, MPH

The US FDA repeatedly pulled monoclonal antibodies against SARS-CoV-2 off the market because modeling studies demonstrated emerging mutational resistance. I wondered if the same challenges will exist for nirsevimab (Beyfortis, Sanofi, AstraZeneca) which have been injected in newborns on a mass indiscriminate basis since October, 2023 for the theoretical prevention of respiratory syncytial virus (RSV).

Continue Reading No Comments

Behind Enemy Lines – Part 1

Written by Robert Malone

Behind Enemy Lines

By Justine Isernhinke

Head of Geopolitics and UAP Research, The Malone Institute www.maloneinstitute.org

In the film Behind Enemy Lines, Owen Wilson plays Lt. Chris Burnett who is stranded behind enemy lines in the former Yugoslavia when his fighter is shot out of the sky.

Continue Reading No Comments